Skip to main content
Clinical reference

Anti-D Information

Anti-D Immunoglobulin (RhIg) is a sterile solution of human IgG antibodies against the RhD antigen. It is given to RhD-negative women so their immune system never becomes sensitised to RhD-positive fetal red cells, preventing Haemolytic Disease of the Fetus and Newborn (HDFN) in the current and every future pregnancy.

Updated: 2026 8 indications 6 dosing rules 6 FAQs

What Anti-D is and why it is needed

What Anti-D actually is

Anti-D Immunoglobulin is purified human IgG anti-RhD, manufactured from the plasma of donors who have been deliberately immunised against the RhD antigen. It is a passive immunisation: the antibodies are supplied ready-made, they do not teach the mother's immune system anything, and they clear any RhD-positive red cells from her circulation before her own immune system can mount a memory response.

Why it is needed — the Rh problem

About 15% of people are RhD-negative. When an RhD-negative mother carries an RhD-positive baby, a small fetomaternal haemorrhage during pregnancy or delivery can push fetal red cells into the maternal circulation. Without Anti-D, roughly 16% of these women will become sensitised: they make permanent anti-D antibodies. Those antibodies cross the placenta in the NEXT pregnancy and destroy the baby's red cells — causing anaemia, hydrops fetalis, kernicterus or stillbirth.

What sensitisation causes

Haemolytic Disease of the Fetus and Newborn (HDFN). Severity ranges from mild neonatal jaundice needing phototherapy to severe anaemia requiring intrauterine transfusion, to fetal death. Because maternal antibodies persist for life, the risk increases with every subsequent RhD-positive pregnancy. Routine Anti-D prophylaxis has cut the incidence of anti-D alloimmunisation by more than 90%.

Indications — when Anti-D must be given

SituationWhoTimingNote
Routine antenatal prophylaxis Every RhD-negative pregnant woman, whether or not any bleeding has occurred 28 weeks (single dose) or 28 + 34 weeks (two-dose schedule) Covers the third-trimester silent fetomaternal haemorrhage.
Within 72 hours of delivery RhD-negative mother of an RhD-positive (or unknown) newborn As soon as possible, ideally ≤72 hours after birth Dose adjusted by Kleihauer-Betke / flow-cytometry FMH volume.
Miscarriage, threatened or complete RhD-negative woman, ≥12 weeks gestation (or any gestation with surgical evacuation) Immediately at presentation Before 12 weeks a smaller 50–120 mcg dose is acceptable where available.
Ectopic pregnancy / molar pregnancy All RhD-negative women At diagnosis or after treatment Trophoblastic tissue expresses RhD.
Termination of pregnancy All RhD-negative women, any gestation Same day as the procedure Dose scales with gestational age.
Invasive prenatal procedures Amniocentesis, CVS, fetal blood sampling, external cephalic version, abdominal trauma Within 72 hours of the event Repeat dosing every 6 weeks if procedures are repeated.
Antepartum haemorrhage Any bleeding episode in an RhD-negative pregnancy Within 72 hours of each episode, repeated every 6 weeks if bleeding continues Do not wait for delivery.
Transfusion of RhD-positive blood RhD-negative girl or woman of childbearing potential wrongly transfused RhD-positive red cells or platelets Immediately on discovery ≈20 mcg per mL of RhD-positive red cells; large volumes may need exchange transfusion.

Dosage and route

ScenarioDoseRouteRepeat
Antenatal prophylaxis (28 weeks) 1500 IU (300 mcg) IM Intramuscular, deltoid or anterolateral thigh Single dose; or 500 IU at 28 and 34 weeks in the two-dose schedule
Postnatal prophylaxis, standard FMH < 4 mL fetal red cells 1500 IU (300 mcg) IM Intramuscular Once, within 72 hours of birth
Large fetomaternal haemorrhage Add 125 IU per extra 1 mL of fetal red cells above 4 mL IM (IV formulations where licensed) Guided by Kleihauer-Betke test at 48–72 hours postpartum
First-trimester event (< 12 weeks) 50–120 mcg (250–600 IU) Intramuscular Once
Events from 12 weeks onwards 300 mcg (1500 IU) Intramuscular Once per event
Wrong-blood-group transfusion ≈20 mcg (100 IU) per 1 mL of RhD-positive red cells Divided IM/IV over days Until the transfused RhD-positive cells are cleared

Timing schedule through pregnancy

Booking visit
Group and RhD type + antibody screen on every pregnant woman.
28 weeks
Give routine antenatal Anti-D to all RhD-negative women. Repeat antibody screen.
Any sensitising event
Give Anti-D within 72 hours — never assume an event is 'too small'.
Delivery
Cord blood group & direct antiglobulin test. Give Anti-D within 72 hours if baby is RhD-positive or unknown.
48–72 hours postpartum
Kleihauer-Betke / flow cytometry to quantify FMH; top-up dose if needed.
After a missed dose
Give it anyway — partial protection persists up to 28 days, though 72 hours remains the target.

Administration technique

  1. Check maternal blood group, RhD type and current antibody screen before every dose.
  2. If anti-D is ALREADY present in the maternal plasma as an immune antibody, Anti-D prophylaxis is useless — refer to obstetric medicine for fetal surveillance.
  3. Deep intramuscular injection into the deltoid (or anterolateral thigh in small adults). Aspirate before injecting.
  4. Never mix Anti-D with other drugs or vaccines in the same syringe. It may be given at a different site on the same day as routine vaccines, including live vaccines.
  5. Observe the patient for 20 minutes afterwards — anaphylaxis is rare but possible in IgA-deficient recipients.
  6. Record the batch number, dose and date in the antenatal record and give the patient a card.
  7. A Kleihauer-Betke acid-elution test at 48–72 hours detects under-dosing; flow cytometry is preferred where available.

Common side effects

  • Pain, tenderness, redness or a small lump at the injection site (most frequent complaint)
  • Low-grade fever, headache, malaise, mild chills
  • Transient skin rash or itching

Rare but serious

  • Anaphylaxis or anaphylactoid reaction — especially in IgA-deficient patients with anti-IgA antibodies
  • Urticaria, arthralgia, myalgia several days after injection
  • Very rarely, disseminated intravascular coagulation in patients receiving large IV doses for wrong-blood-group transfusion

Contraindications

  • Known hypersensitivity to human immunoglobulin preparations or to any excipient (e.g. glycine, polysorbate 80)
  • RhD-positive women and RhD-negative women already alloimmunised to RhD (no benefit)
  • Severe thrombocytopenia or coagulopathy — prefer an IV formulation over intramuscular injection
  • IgA deficiency with documented anti-IgA antibodies — use an IgA-depleted product or avoid

Storage and cold chain

  • Store at 2 °C to 8 °C. DO NOT FREEZE — a frozen vial must be discarded.
  • Protect from light in the original carton.
  • After reconstitution use immediately; some products allow up to 4 hours at 2–8 °C.
  • The cold chain is the single most common cause of Anti-D failure in district-level practice in Bangladesh — verify the vaccine-carrier temperature log before injecting.

FAQ

Yes. The antenatal dose only protects the weeks it was given for. A separate postnatal dose within 72 hours of birth is required whenever the baby is RhD-positive or the baby's group is unknown.

If paternity is certain and the father is truly RhD-negative, the fetus will be RhD-negative and prophylaxis is unnecessary. In practice most guidelines still recommend it unless the father's group is confirmed, because a single missed dose risks every future pregnancy.

Give it anyway. Protection declines but does not vanish — evidence supports benefit up to 28 days after the event. Do not withhold a late dose.

No. Anti-D does not cross into the fetus in a clinically meaningful amount and has an excellent safety record over five decades of use. The small amount that does cross can cause a weakly positive direct antiglobulin test in the newborn, which is harmless.

Yes, including live attenuated vaccines. Use a separate syringe and a separate injection site. Rubella vaccine given postpartum alongside Anti-D is standard practice.

Anti-D is available in most district and upazila health complexes and in private hospitals. BloodFerry's medical shop lists Rhophylac Anti-D 300 mcg under the Medicine category; you can order it for ৳10 delivery inside Kalai Upazila.

Sources

  • ACOG Practice Bulletin No. 181 — Prevention of Rh D Alloimmunization
  • RCOG Green-top Guideline No. 65 — The Management of Rhesus Isoimmunisation in Pregnancy
  • WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience
  • Bangladesh National Guideline on Maternal & Neonatal Care, DGHS

This is general information and is not a substitute for a doctor’s advice.

Quick dose card

Antenatal prophylaxis (28 weeks)
1500 IU (300 mcg) IM
Intramuscular, deltoid or anterolateral thigh
Postnatal prophylaxis, standard FMH < 4 mL fetal red cells
1500 IU (300 mcg) IM
Intramuscular
Large fetomaternal haemorrhage
Add 125 IU per extra 1 mL of fetal red cells above 4 mL
IM (IV formulations where licensed)
First-trimester event (< 12 weeks)
50–120 mcg (250–600 IU)
Intramuscular

Anti-D in the shop

Rhophylac Anti-D 300 mcg is listed under the Medicine category.

Shop Compatibility Reviews

Admin-managed entries

8 articles
Routine antenatal prophylaxis

Every RhD-negative pregnant woman, whether or not any bleeding has occurred. Covers the third-trimester silent fetomaternal haemorrhage.

Timing
28 weeks (single dose) or 28 + 34 weeks (two-dose schedule)
Dose
See the dosing schedule
Within 72 hours of delivery

RhD-negative mother of an RhD-positive (or unknown) newborn. Dose adjusted by Kleihauer-Betke / flow-cytometry FMH volume.

Timing
As soon as possible, ideally ≤72 hours after birth
Dose
See the dosing schedule
Miscarriage, threatened or complete

RhD-negative woman, ≥12 weeks gestation (or any gestation with surgical evacuation). Before 12 weeks a smaller 50–120 mcg dose is acceptable where available.

Timing
Immediately at presentation
Dose
See the dosing schedule
Ectopic pregnancy / molar pregnancy

All RhD-negative women. Trophoblastic tissue expresses RhD.

Timing
At diagnosis or after treatment
Dose
See the dosing schedule
Termination of pregnancy

All RhD-negative women, any gestation. Dose scales with gestational age.

Timing
Same day as the procedure
Dose
See the dosing schedule
Invasive prenatal procedures

Amniocentesis, CVS, fetal blood sampling, external cephalic version, abdominal trauma. Repeat dosing every 6 weeks if procedures are repeated.

Timing
Within 72 hours of the event
Dose
See the dosing schedule
Antepartum haemorrhage

Any bleeding episode in an RhD-negative pregnancy. Do not wait for delivery.

Timing
Within 72 hours of each episode, repeated every 6 weeks if bleeding continues
Dose
See the dosing schedule
Transfusion of RhD-positive blood

RhD-negative girl or woman of childbearing potential wrongly transfused RhD-positive red cells or platelets. ≈20 mcg per mL of RhD-positive red cells; large volumes may need exchange transfusion.

Timing
Immediately on discovery
Dose
See the dosing schedule
Live Support
Online
Guest Ask AI
Live AI Help
Assistant Ready
Instant answers on blood groups, Anti-D, guidelines and shop orders.